Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trega Biosciences (TRGA), formerly HPIP -- Ignore unavailable to you. Want to Upgrade?

To: E.J. Neitz Jr who wrote (62)	5/29/1998 3:40:00 PM
From: E.J. Neitz Jr	Read Replies (1) \| Respond to of 152

H&Q Research Summary--BUY---2/98 Hambrecht & Quist issued a Company Report on February 13, 1998 for Trega Biosci. On February 13, 1998 Hambrecht & Quist's Research Department issued a 2 page Company Report on Trega Biosci. Report highlights: 'A BUY rating was maintained. It was announced that Warner-Lambert will purchase $1.5 million of the company's common stock after identifying a series of lead compounds from the company's combinatorial libraries, which are active against an important biological target. This achievement validates the company's technology and will lead to the signing of additional pharmaceutical partners.' Report No.: F0085980 The full text of this and over 30,000 other reports are available for purchase from Zacks. --------------------------------------------------------------------------------